Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
CAMBRIDGE, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. Chairman of the Board of Directors Sandford D. Smith is scheduled to present on Thursday, January 14, 2016 at 8:00 a.m. PST (11:00 a.m. EST). Mr. Smith will also introduce Aegerion’s newly appointed Chief Executive Officer, Mary Szela.
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Aegerion’s website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations 857-242-5024
